Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind study of intravenous plus inhaled colistin methanesulfonate sodium for carbapenem-resistant Gram-negative HAP/VAP
CTR20260813Phase 2Active
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of colistimethate sodium in hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Jul 2026; status: active.
02
Drugs
colistimethate sodium
03
Conditions
hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on CTR20260813.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20260813.